Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of us food and drug administration approvals

Chul Kim, Vinay Prasad

Research output: Contribution to journalArticle

138 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)1992-1994
Number of pages3
JournalJAMA Internal Medicine
Volume175
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Endpoint Determination
Drug Approval
United States Food and Drug Administration
Survival Analysis
Antineoplastic Agents
Biomarkers
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{c6b8448411c8437ba7b10d6ee0ca9644,
title = "Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of us food and drug administration approvals",
author = "Chul Kim and Vinay Prasad",
year = "2015",
month = "12",
day = "1",
doi = "10.1001/jamainternmed.2015.5868",
language = "English (US)",
volume = "175",
pages = "1992--1994",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival

T2 - An analysis of 5 years of us food and drug administration approvals

AU - Kim, Chul

AU - Prasad, Vinay

PY - 2015/12/1

Y1 - 2015/12/1

UR - http://www.scopus.com/inward/record.url?scp=84964837459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964837459&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2015.5868

DO - 10.1001/jamainternmed.2015.5868

M3 - Article

C2 - 26502403

AN - SCOPUS:84964837459

VL - 175

SP - 1992

EP - 1994

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 12

ER -